CBAYのチャート
CBAYの企業情報
| symbol | CBAY |
|---|---|
| 会社名 | CymaBay Therapeutics Inc （シマベ―・セラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 CymaBay Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases including serious rare and orphan diseases. The Company''s product candidates include Arhalofenate MBX-8025 and MBX-2982. Arhalofenate is used to treat gout. MBX-8025 is a selective agonist for the peroxisome proliferator-activated receptor delta (PPARd). The Company has completed over five Phase I clinical studies and a Phase II clinical study for MBX-8025. MBX-2982 is an oral G-protein coupled receptor agonist being evaluated as a therapeutic agent for patients with Type 2 diabetes (T2DM) with a dual mechanism including direct effects and indirect effects mediated by gastrointestinal hormones known as incretins on glucose-dependent insulin secretion as well as potentially beneficial effects on islet health. The Company has completed over four Phase I clinical studies and a Phase II clinical study for MBX-2982. シマベ―・セラピュ―ティクスは、米国のバイオ医薬品企業。医療が必要な代謝と希少疾患を治療するための治療法の開発に焦点を当てる。主要製品候補｢Arhalofenate｣は、痛風の治療のために開発される。関節における痛風の痛みを伴う発作の予防及び腎臓による尿酸の排泄を促進することで血清尿酸の低下を促す。 cymabay therapeutics is a clinical-stage biopharmaceutical company located in the san francisco bay area focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases. we are committed to developing breakthrough medicines that improve the lives of patients and their families. cymabay was seeded with the assets from an earlier metabolic disease company in which more than $120m was invested to produce a robust pipeline. |
| 本社所在地 | 7999 Gateway Blvd. Suite 130 Newark CA 94560 USA |
| 代表者氏名 | Robert James Wills ロバートジェームズウィルス |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 510-293-8800 |
| 設立年月日 | 32417 |
| 市場名 | NASDAQ National Market System |
| ipoyear | ―年 |
| 従業員数 | － |
| url | www.cymabay.com |
| nasdaq_url | https://www.nasdaq.com/symbol/cbay |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -41.52900 |
| 終値（lastsale） | 10.51 |
| 時価総額（marketcap） | 620644906.98 |
| 時価総額 | 時価総額（百万ドル） 624.77860 |
| 売上高 | 売上高（百万ドル） 5.20700 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 412.69960 |
| 当期純利益 | 当期純利益（百万ドル） -47.81300 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 CymaBay Therapeutics Inc revenues decreased from $4.8M to $0K. Net loss increased from $14.3M to $34.5M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and Develop increase from $7.5M to $22.6M (expense) Other (expense) income Net increase of 48% to $4.7M (expense). |
CBAYのテクニカル分析
CBAYのニュース
CymaBay Therapeutics Chief Financial Officer Awarded $3.24M Worth of Stock Options 2023/05/23 15:04:23 Benzinga
Harish Shantharam , Chief Financial Officer at CymaBay Therapeutics (NASDAQ: CBAY ), reported a large acquisition of company stock options on May 22, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Monday showed that Shantharam, Chief Financial Officer at CymaBay Therapeutics, a company in the Health Care sector, was just awarded stock options worth 360,000 shares of CBAY. The options give Shantharam the right to buy the company''s stock at $8.76 per share. CymaBay Therapeutics shares are trading up 2.68% at $8.99 at the time of this writing on Tuesday morning. Since the current price is $8.99, this makes Shantharam''s 360,000 … Full story available on Benzinga.com
Why CymaBay Therapeutics Stock Nose-Dived This Week 2023/05/19 21:59:16 The Motley Fool
Investors did not warmly greet the latest news from the biotech.
Gout Therapeutics Market to See Huge Demand by 2030: Regeneron Pharmaceuticals, CymaBay Therapeutics, LG Life Sciences 2023/05/18 16:30:55 EIN News Marijuana
Gout Therapeutics Market Current Status and Future Prospects PUNE, MAHARASHTRA, INDIA, May 18, 2023 /EINPresswire.com/ -- According to HTF Market Intelligence, the Global Gout Therapeutics market to witness a CAGR of 13.7% during forecast period …
CymaBay Therapeutics Inc. (NASDAQ: CBAY) Bullish Stock Forecast for 2023 with $19.00 Per Share 2023/05/16 17:30:00 Marketing Sentinel
In the latest trading session, 1.43 million CymaBay Therapeutics Inc. (NASDAQ:CBAY) shares changed hands as the company’s beta touched 0.27. With the company’s most recent per share price at $9.57 changed hands at -$0.83 or -7.93% at last look, the market valuation stands at $1.02B. CBAY’s current price is a discount, trading about -17.24% off … CymaBay Therapeutics Inc. (NASDAQ: CBAY) Bullish Stock Forecast for 2023 with $19.00 Per Share Read More »
CymaBay Therapeutics, Inc. (CBAY) Q1 2023 Earnings Call Transcript 2023/05/16 02:52:02 Seeking Alpha
CymaBay Therapeutics, Inc. (NASDAQ:NASDAQ:CBAY) Q1 2023 Earnings Conference Call May 15, 2023 4:30 PM ETCompany ParticipantsPaul Quinlan - General CounselSujal Shah - President and Chief…
CymaBay Therapeutics (NASDAQ:CBAY) Hits New 52-Week High at $10.79 2023/04/30 07:28:26 The AM Reporter
CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Rating)’s share price hit a new 52-week high on Friday . The stock traded as high as $10.79 and last traded at $10.79, with a volume of 383730 shares changing hands. The stock had previously closed at $10.30. Analyst Upgrades and Downgrades Several analysts have weighed in on CBAY […]
Four Potential Breakout Stocks For The Rest Of The Week 2023/04/19 12:58:13 Benzinga
In trading, there will always be elegance in simplicity. If your trading operation lacks a cadre of PhDs to crunch data like Renaissance Technologies or D.E. Shaw, simplicity will always trump excessive sophistication. The other bit of trading wisdom that should rarely be violated is “the trend is your friend.” Below, we take a look at four of the most significant bullish trends in the market right now. One important caveat with regard to these four stocks is that all of them are triggering very high RSI readings and could be due for sharp pullbacks as a result. Nevertheless, these stocks are making extremely powerful moves and there is a strong likelihood that the coming days could see an extension of price gains. Play these stocks with relatively tight stops and look for price to extend beyond your entry quickly in order to confirm continued strength and momentum. The screen used to identify these four names was stocks with a market cap above $300 million, recording new 52-week highs on above 200% average volume on Monday.
CymaBay Therapeutics Files Mixed Shelf 2023/03/23 20:53:04 Investing.com
https://www.investing.com/news/assorted/cymabay-therapeutics-files-mixed-shelf-432SI-3038495
CymaBay Therapeutics, Inc. (CBAY) Q4 2022 Earnings Call Transcript 2023/03/17 00:43:08 Seeking Alpha
CymaBay Therapeutics, Inc. (NASDAQ:NASDAQ:CBAY) Q4 2022 Earnings Conference Call March 16, 2023 4:30 PM ETCompany ParticipantsPaul Quinlan - General CounselSujal Shah - Chief Executive…
CymaBay Therapeutics GAAP EPS of -$0.30 misses by $0.01 2023/03/16 20:08:47 Seeking Alpha
CymaBay Therapeutics press release (CBAY): Q4 GAAP EPS of -$0.30 misses by $0.01.Held $135.5 million in cash, cash equivalents and investments as of December 31, 2022.
CymaBay Therapeutics Inc. (CBAY) Q2 2022 Earnings Call Transcript 2022/08/12 08:30:53 The Motley Fool
CBAY earnings call for the period ending June 30, 2022.
Cymabay Therapeutics, Inc. (CBAY) CEO Sujal Shah on Q2 2022 Results - Earnings Call Transcript 2022/08/12 03:16:06 Seeking Alpha
Cymabay Therapeutics, Inc. (NASDAQ:NASDAQ:CBAY) Q2 2022 Earnings Conference Call August 11, 2022, 16:30 ET Company Participants Paul Quinlan - General Counsel, Chief Compliance Officer…
CymaBay Therapeutics: Q2 Earnings Insights 2022/08/11 20:59:31 Benzinga
CymaBay Therapeutics (NASDAQ: CBAY ) reported its Q2 earnings results on Thursday, August 11, 2022 at 04:06 PM. Here''s what investors need to know about the announcement. Earnings CymaBay Therapeutics missed estimated earnings by 3.33%, reporting … Full story available on Benzinga.com